steidl laboratory

Recent Publications (Selection)

 

Ebralidze A, Guibal F, Steidl U, Zhang P, Lee S, Batholdy B, Alberich-Jorda M,
Petkova V, Rosenbauer F, Huang G, Dayaram T, Klupp J, O'Brien KB, Will B,
Hoogenkamp M, Bonifer C, Tenen DG.
 PU.1 expression is modulated by the balance of functional sense and antisense RNAs
regulated by a shared cis-regulatory element.
Genes Dev. 2008; 22:2085-92

Bruns I*, Steidl U*, Fischer JC, Czibere A, Kobbe G, Raschke S, Singh R, Fenk R,
Rosskopf M, Pechtel S, von Haeseler A, Wernet P, Tenen DG, Haas R, Kronenwett R.
*contributed equally 
 Pegylated G-CSF mobilizes CD34+ cells with different stem and progenitor subsets
and distinct functional properties in comparison with unconjugated G-CSF.
Haematologica. 2008; 93:347-355. 

Steidl U
*, Steidl C*, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F,
Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB,
Verhaak RG, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T,
Griesinger F, Tenen DG. *contributed equally
 A distal single nucleotide polymorphism alters long-range regulation of the PU.1
gene in acute myeloid leukemia.
J Clin Invest. 2007; 117:2611-20.

Neukirchen J, Meier A, Rohrbeck A, Garcia-Pardillos G, Steidl U, Fenk R, Haas
R, Kronenwett R, Rohr UP.
 The proteasome inhibitor bortezomib acts differently in combination with p53 gene
transfer or cytotoxic chemotherapy on NSCLC cells.
Cancer Gene Ther. 2007; 14:431-9.

Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis
AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M,
Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA.
 Serum proteome profiling detects myelodysplastic syndromes and identifies CXC
chemokine ligands 4 and 7 as markers for advanced disease.
Proc Natl Acad Sci U S A. 2007; 104:1307-12. 

Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub
T, Meyerson M, Tenen DG, Shapiro GI, Halmos B.
 Transcriptional profiling identifies cyclin D1 as a critical downstream effector
of mutant epidermal growth factor receptor signaling.
Cancer Res. 2006; 66:11389-98.

Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, Klippel S,
Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegué E,
Libermann TA, Delwel R, Tenen DG.
 Essential role of Jun family transcription factors in PU.1 knockdown-induced
leukemic stem cells.
Nat Genet. 2006; 38:1269-77.

Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R,
Kobbe G.
 
Sustained G-CSF plasma levels following administration of pegfilgrastim fasten
neutrophil reconstitution after high-dose chemotherapy and autologous blood stem
cell transplantation in patients with multiple myeloma.
Exp Hematol. 2006; 34:1296-302.

Graef T, Steidl U, Nedbal W, Rohr U, Fenk R, Haas R, Kronenwett R.
 
Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis.
Angiogenesis. 2005; 8:361-72.
 
Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL, Clayton LK,
Wagner K, Scheller M, Iwasaki H, Liu C, Hackanson B, Akashi K, Leutz A, Rothstein
TL, Plass C, Tenen DG.
 Lymphoid cell growth and transformation are suppressed by a key regulatory
element of the gene encoding PU.1.
Nat Genet. 2006; 38:27-37.

Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C,
Hildebrandt B, Haas R, Heyll A, Kobbe G; the West German Myeloma Study Group.
 
High-dose idarubicin, cyclophosphamide and melphalan as conditioning for
autologous stem cell transplantation increases treatment-related mortality in
patients with multiple myeloma: results of a randomised study.
Br J Haematol. 2005; 30:588-94.

Steidl U, Schroeder T, Steidl C, Kobbe G, Graef T, Bork S, Pechtel S,
Kliszewski S, Kuendgen A, Rohr UP, Fenk R, Schroeder M, Haase D, Haas R,
Kronenwett R.
 Distinct gene expression pattern of malignant hematopoietic stem and progenitor
cells in polycythemia vera.
Ann N Y Acad Sci. 2005; 1044:94-108.

Rosenbauer F, Koschmieder S, Steidl U, Tenen DG.
 
Effect of transcription-factor concentrations on leukemic stem cells.
Blood. 2005; 106:1519-24.

Kronenwett R, Butterweck U, Steidl U, Kliszewski S, Neumann F, Bork S, Blanco
ED, Roes N, Gräf T, Brors B, Eils R, Maercker C, Kobbe G, Gattermann N, Haas R.
 Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and
progenitor cells in chronic myelogenous leukemia.
Oncogene. 2005; 24:5313-24.

Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Gräf T, Rohr UP,
Bork S, Kronenwett R, Haas R, Kobbe G.
 Successful transplantation of peripheral blood stem cells mobilized by
chemotherapy and a single dose of pegylated G-CSF in patients with multiple
myeloma.
Bone Marrow Transplant. 2005; 35:33-6.

Fenk R, Hoyer B, Steidl U, Kondakci M, Graef T, Heuk R, Ruf L, Strupp C,
Neumann F, Rohr UP, Hildebrandt B, Haas R, Kobbe G.
 Single-agent thalidomide for treatment of first relapse following high-dose
chemotherapy in patients with multiple myeloma.
Leukemia. 2005; 19:156-9.

Fenk R, Ak M, Kobbe G, Steidl U, Arnold C, Korthals M, Hünerlitürkoglu A,
Rohr UP, Kliszewski S, Bernhardt A, Haas R, Kronenwett R.
 Levels of minimal residual disease detected by quantitative molecular monitoring
herald relapse in patients with multiple myeloma.
Haematologica. 2004; 89:557-66.

Steidl U, Bork S, Schaub S, Selbach O, Seres J, Aivado M, Schroeder T, Rohr
UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Bornstein SR, Haas HL, Kobbe G,
Tenen DG, Haas R, Kronenwett R.
 Primary human CD34+ hematopoietic stem and progenitor cells express functionally
active receptors of neuromediators.
Blood. 2004; 104:81-8.

Steidl U, Kronenwett R, Haas R.
 
Differential gene expression underlying the functional distinctions of primary
human CD34+ hematopoietic stem and progenitor cells from peripheral blood and
bone marrow.
Ann N Y Acad Sci. 2003; 996:89-100.

Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P,
Aivado M, Koch J, Modlich O, Bojar H, Gattermann N, Haas R.
 
Gene expression profiling identifies significant differences between the
molecular phenotypes of bone marrow-derived and circulating human CD34+
hematopoietic stem cells.
Blood. 2002; 99:2037-44.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Click here to log in